PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-90.13%
Revenue decline while Biotechnology median is 0.00%. Seth Klarman would investigate if market share loss is temporary.
No Data
No Data available this quarter, please select a different quarter.
-148.93%
Gross profit decline while Biotechnology median is 0.00%. Seth Klarman would investigate competitive position.
-595.65%
Margin decline while Biotechnology median is 0.00%. Seth Klarman would investigate competitive position.
15.04%
R&D growth exceeding 1.5x Biotechnology median of 5.02%. Jim Chanos would check for wasteful spending.
33.15%
G&A change of 33.15% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.43%
Operating expenses growth exceeding 1.5x Biotechnology median of 9.03%. Jim Chanos would check for waste.
20.43%
Total costs growth exceeding 1.5x Biotechnology median of 9.17%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
3.01%
D&A growth exceeding 1.5x Biotechnology median of 0.70%. Jim Chanos would check for overinvestment.
-24.86%
EBITDA decline while Biotechnology median is -7.17%. Seth Klarman would investigate causes.
-1164.87%
EBITDA margin decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-24.41%
Operating income decline while Biotechnology median is -9.11%. Seth Klarman would investigate causes.
-1160.31%
Operating margin decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-17.39%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-24.71%
Pre-tax income decline while Biotechnology median is -9.04%. Seth Klarman would investigate causes.
-1163.35%
Pre-tax margin decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-24.71%
Net income decline while Biotechnology median is -8.54%. Seth Klarman would investigate causes.
-1163.35%
Net margin decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-23.33%
EPS decline while Biotechnology median is -2.52%. Seth Klarman would investigate causes.
-23.33%
Diluted EPS decline while Biotechnology median is -1.85%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.